IVERIC bio (ISEE) Competitors

Zai Lab (NASDAQ:ZLAB) and IVERIC bio (NASDAQ:ISEE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.

Do analysts recommend ZLAB or ISEE?

Zai Lab presently has a consensus price target of $83.10, suggesting a potential upside of 248.72%. IVERIC bio has a consensus price target of $25.75, suggesting a potential downside of 35.54%. Given IVERIC bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Zai Lab is more favorable than IVERIC bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
IVERIC bio	0 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is ZLAB or ISEE more profitable?

IVERIC bio has a net margin of 0.00% compared to IVERIC bio's net margin of -156.07%. IVERIC bio's return on equity of -38.48% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-156.07%	-38.48%	-32.78%
IVERIC bio	N/A	-57.00%	-46.15%

Which has more risk and volatility, ZLAB or ISEE?

Zai Lab has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, IVERIC bio has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

Which has higher valuation and earnings, ZLAB or ISEE?

IVERIC bio has lower revenue, but higher earnings than Zai Lab. IVERIC bio is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$215.04M	10.95	-$443.29M	-$4.09	-5.83
IVERIC bio	N/A	N/A	-$185.21M	-$1.76	-22.70

Does the media favor ZLAB or ISEE?

In the previous week, Zai Lab had 1 more articles in the media than IVERIC bio. MarketBeat recorded 1 mentions for Zai Lab and 0 mentions for IVERIC bio. IVERIC bio's average media sentiment score of 1.87 beat Zai Lab's score of 0.45 indicating that Zai Lab is being referred to more favorably in the media.

Company	Overall Sentiment
Zai Lab	Very Positive
IVERIC bio	Neutral

Does the MarketBeat Community believe in ZLAB or ISEE?

Zai Lab received 153 more outperform votes than IVERIC bio when rated by MarketBeat users. Likewise, 62.50% of users gave Zai Lab an outperform vote while only 42.86% of users gave IVERIC bio an outperform vote.

Company	Underperform	Outperform
Zai Lab	Outperform Votes 210 62.50%	Underperform Votes 126 37.50%
IVERIC bio	Outperform Votes 57 42.86%	Underperform Votes 76 57.14%

Do institutionals & insiders believe in ZLAB or ISEE?

43.7% of Zai Lab shares are held by institutional investors. 5.2% of Zai Lab shares are held by company insiders. Comparatively, 2.7% of IVERIC bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Zai Lab beats IVERIC bio on 14 of the 17 factors compared between the two stocks.